BLIS K12 Receives “No Objection” GRAS Letter From FDA
19 Feb 2016 --- Oral-health probiotic BLIS K12 has received a “Letter of No Objection” from the US Food and Drink Administration (FDA) for its self-affirmed notification of Generally Recognized As Safe (GRAS) status.
The patented probiotic strain of Streptococcus salivarius, BLIS K12, has been studied for benefits to ear and throat health in children and adults, including reducing incidence of halitosis and Streptococal pharyngitis.
BLIS K12 developer Blis Technologies (Dunedin, New Zealand) and North America distributor Stratum Nutrition (Saint Charles, MO) celebrated the “No Objection” GRAS status as key to opening more markets for the probiotic:
“It adds a new level of credibility for BLIS K12 and puts the conversations with larger consumer food and beverage companies in the US on a stronger footing,” said Peter Fennessy, board chairman, Blis Technologies.
“Many of those companies are, quite rightly, risk averse. Therefore, having the non-objection notification from the FDA offers an additional level of confidence and makes it clearer where BLIS K12 fits within the category,” Fennessy added.
Jeremy Moore, managing director of Stratum Nutrition, added, “Very few ingredients in this space go to this level, so it is a definite feather in the cap for Blis.”
Through the GRAS program, companies may submit their determination, supported by research and expert review, that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions regarding the notice submitted.
24 Apr 2024 --- US-based ADM’s DE111 (Bacillus subtilis) probiotic targeting gut health has been approved by China’s National Health Commission after meeting...Read More
04 Apr 2024 --- A new study suggests that NutriLeads’ fermentation mechanisms enable its precision prebiotic BeniCaros to increase the beneficial bacteria in the...Read More
26 Mar 2024 --- New research finds a synergistic effect of a synbiotic by Clasado Biosciences and Probi — combining Clasado’s prebiotic Bimuno GOS...Read More
25 Mar 2024 --- The Danish biosolutions company Novonesis is launching a human milk oligosaccharides (HMOs) research consortium alongside the University of California...Read More
13 Mar 2024 --- New Zealand-based Blis Technologies has released a whitepaper featuring two recent studies exploring the effects of its probiotic supplement Blis K12 in...Read More